Literature DB >> 6713381

DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one.

N W Gibson, J A Hickman, L C Erickson.   

Abstract

Normal (IMR-90) and SV40-transformed (VA-13) human embryo cells were treated with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one (M&B 39565), and the effects of the drug on cell viability and cellular DNA integrity were studied. The effects of M&B 39565 were compared with one of its potential decomposition products 5-[3-(2-chloroethyl)triazen-1 -yl]imidazole-4-carboxamide (MCTIC). M&B 39565 and MCTIC were 5- to 6-fold more toxic to VA-13 cells than to IMR-90 cells for drug concentrations which produced a 2-log cell kill, as measured by colony-forming assays. Using alkaline elution analysis, VA-13 cells exhibited concentration-dependent DNA interstrand cross-link formation. In IMR-90 cells, little or no interstrand cross-link formation was detected. The DNA interstrand cross-link formation in VA-13 cells was found to peak 12 hr after drug removal. A linear correlation between DNA interstrand cross-link formation and log cell kill was observed in VA-13 cells but not in IMR-90 cells. DNA-protein cross-link formation was found to be comparable in both cell lines for each drug, suggesting that drug penetration and intracellular drug reactivity were similar. Initial chemical decomposition studies suggest that both M&B 39565 and MCTIC may produce a chloroethyldiazo species. This species has been implicated in the formation of chloroethyl-DNA adducts which convert to DNA interstrand cross-links in mammalian cells treated with chloroethylnitrosoureas [Erickson et al., Nature (Lond.), 288: 727, 1980]. These data suggest that DNA interstrand cross-link formation may be a common mechanism for the in vitro cytotoxicity of M&B 39565 and MCTIC.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713381

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma.

Authors:  Carlo Palmieri; Cathryn Brock; Edward S Newlands
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

2.  Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.

Authors:  Mahendra Patel; Cynthia McCully; Karen Godwin; Frank M Balis
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

3.  Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.

Authors:  P Herait; J P Armand; M Benahmed; C Domenge; X Fontana; G Recondo; E Cvitkovic; F M Delgado
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

4.  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

Authors:  C Dive; P Workman; J V Watson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma.

Authors:  M Broggini; E Erba; L Morasca; C Horgan; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

Authors:  M McKeage; P Dady; M Clear; A MacDonald
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.

Authors:  P Herait; P Rougier; J Oliveira; F M Delgado; F May-Levin; M Hayat; J P Armand
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

Review 9.  Role of temozolomide in pediatric brain tumors.

Authors:  Giuseppe Barone; Palma Maurizi; Giampiero Tamburrini; Riccardo Riccardi
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

10.  Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.

Authors:  C Goddard; J A Slack; M F Stevens
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.